Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain.
Maria MarequePau MontesinosPatricia FontJosé María GuineaAdolfo de la FuenteJavier SotoItziar OyagüezJames BrockbankTamara IglesiasJulia LlinaresJorge SierraPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
This simulation suggests that GO + SOC could be a cost-effective option for treatment of patients with de novo AML in first line.